Alnara Therapeutics (Cambridge, MA) a clinical-stage biopharmaceutical company focused on liprotamase, a pancreatic enzyme replacement therapy, for the treatment of pancreatic insufficiency associated with cystic fibrosis, chronic pancreatitis, pancreatic cancer, pancreatectomy and other pancreatic conditions, closed a $35M Series B financing. Participants include MPM Capital, Third Rock Ventures, Frazier Healthcare and Bessemer Venture Partners.